ArticleMalaria journal2026
Droplet digital PCR assays for Pvmdr1 and Pvcrt-o gene copy number variation determination in Plasmodium vivax.
Article in Malaria journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundmdr1 and crt-o amplification in Plasmodium vivax has been associated with antimalarial drug resistance and could thus be a molecular marker. Accurate copy number variation (CNV) quantification could provide valuable insights for monitoring resistance trends.
objectivesTo develop a duplex digital PCR (ddPCR) assay for the simultaneous absolute pvmdr1 and pvcrt-o quantification using pvtubulin as a single-copy internal reference.
methodsDuplex ddPCR assays were optimized to target pvmdr1/pvtubulin and pvcrt-o/pvtubulin. CNV was calculated as the ratio of the absolute concentration of the target gene to the reference.
resultsddPCR assays were successfully developed and validated. The quantification limits for assays targeting pvmdr1/pvtubulin and pvcrt-o/pvtubulin, based on pvtubulin concentration, were 22.4 ± 3.5 and 21.5 ± 2.6 copies/µL, respectively. Analysis of field samples from Tak (N = 25) and Kanchanaburi Provinces (N = 97), Thailand, revealed that in 2008, 16% of isolates from Tak carried multiple copies of pvmdr1 and all samples possessed a single copy of pvcrt-o. In contrast, samples collected from the Kanchanaburi Province during 2023-2025 showed no evidence of multiple copies of either gene.
conclusionThis newly developed ddPCR assay provides a robust and highly reproducible tool for monitoring P. vivax drug resistance markers in endemic regions and a potential approach in surveillance programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.